KCL-00001335 - CANTOP

A Tender Notice
by KING'S COLLEGE LONDON

Source
Contracts Finder
Type
Contract (Services)
Duration
3 year
Value
£600K-£1M
Sector
INDUSTRIAL
Published
29 Jun 2021
Delivery
01 Sep 2021 to 02 Sep 2024
Deadline
22 Jul 2021 17:00

Concepts

Location

Geochart for 1 buyers and 0 suppliers

1 buyer

Description

CANTOP-RCT is a non-commercial, UK multi-centre, pragmatic, parallel group, randomised, double-blind, placebo-controlled clinical trial of cannabidiol (CBD) as a treatment in early psychosis. The primary objective of this trial is to test whether treatment with CBD improves psychotic symptoms when added to Treatment as Usual (TAU) in Clinical High Risk (CHR) patients. Patients will be randomised in a 1:1 ratio to either TAU + Cannabidiol or TAU + Placebo. The sample size is 300 patients (n=150 per arm). Patient recruitment will take place over 3 years. The total duration from first patient visit, to last patient visit, is anticipated to be 42 months. The trial is co-sponsored by King's College London and South London & Maudsley NHS Foundation Trust and is funded by the National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme. Service providers are invited to tender for the manufacture of the investigational medicinal products (including procurement of GMP grade CBD), complete associated stability and QC validation/testing, QP release, and store and distribute the IMP to UK trial sites. In order to compliantly participate in the tender process, all bidders are expected to fulfill the scope and specification requirements.

CPV Codes

  • 71900000 - Laboratory services

Other Information

Is a Recurrent Procurement Type? : No Additional information on how to apply for this contract https://in-tendhost.co.uk/kcl/aspx/

Reference

Domains